Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Neal Franz

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Pediatric Neurology|November 15, 2018
Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis ComplexJurriaan M Peters, Anna Prohl, Kush Kapur, et al.
Frontiers in Neurology|April 26, 2021
Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous ReportsKate Mowrey, Hope Northrup, Peyton Rougeau, et al.
Plos One|February 26, 2013
Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosisIzabela A Malinowska, Nancy Lee, Vidhya Kumar, et al.
Journal of Child Neurology|March 2, 2012
Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndromeElizabeth D Tate, Michael R Pranzatelli, Steven J Verhulst, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Plos One|September 15, 2011
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decreaseSandra L Dabora, David Neal Franz, Stephen Ashwal, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 15, 2018
Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experienceDarcy A Krueger, Jamie K Capal, Paolo Curatolo, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Annals of the Child Neurology Society|December 27, 2024
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy resultsJamie K Capal, David M Ritter, David Neal Franz, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Pediatric Neurology|November 15, 2018
Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis ComplexJurriaan M Peters, Anna Prohl, Kush Kapur, et al.
Frontiers in Neurology|April 26, 2021
Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous ReportsKate Mowrey, Hope Northrup, Peyton Rougeau, et al.
Plos One|February 26, 2013
Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosisIzabela A Malinowska, Nancy Lee, Vidhya Kumar, et al.
Journal of Child Neurology|March 2, 2012
Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndromeElizabeth D Tate, Michael R Pranzatelli, Steven J Verhulst, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Plos One|September 15, 2011
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decreaseSandra L Dabora, David Neal Franz, Stephen Ashwal, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 15, 2018
Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experienceDarcy A Krueger, Jamie K Capal, Paolo Curatolo, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Annals of the Child Neurology Society|December 27, 2024
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy resultsJamie K Capal, David M Ritter, David Neal Franz, et al.
Pageof 4